What is Zacks Research’s Forecast for DNLI FY2024 Earnings?

Denali Therapeutics Inc. (NASDAQ:DNLI) – Stock analysts at Zacks Research decreased their FY2024 earnings per share (EPS) estimates for shares of Denali Therapeutics in a report released on Tuesday, January 28th. Zacks Research analyst A. Chakraborty now anticipates that the company will post earnings of ($2.77) per share for the year, down from their previous estimate of ($2.71). The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.73) per share. Zacks Research also issued estimates for Denali Therapeutics’ Q4 2024 earnings at ($0.87) EPS, Q1 2025 earnings at ($0.83) EPS, Q2 2025 earnings at ($0.84) EPS, Q3 2025 earnings at ($0.83) EPS, Q4 2025 earnings at ($0.87) EPS, FY2025 earnings at ($3.37) EPS, Q1 2026 earnings at ($0.86) EPS, Q2 2026 earnings at ($0.89) EPS, Q3 2026 earnings at ($0.85) EPS, Q4 2026 earnings at ($0.90) EPS and FY2026 earnings at ($3.51) EPS.

Several other brokerages have also recently issued reports on DNLI. HC Wainwright dropped their price objective on Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Robert W. Baird assumed coverage on Denali Therapeutics in a research report on Tuesday, January 7th. They set an “outperform” rating and a $31.00 price target on the stock. Jefferies Financial Group lifted their price objective on Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a report on Friday, November 1st. Baird R W raised shares of Denali Therapeutics to a “strong-buy” rating in a research note on Tuesday, January 7th. Finally, The Goldman Sachs Group cut their target price on shares of Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating on the stock in a research report on Tuesday. Two equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $38.00.

Denali Therapeutics Stock Up 0.7 %

Shares of NASDAQ:DNLI opened at $23.58 on Friday. The firm’s 50 day simple moving average is $22.45 and its 200-day simple moving average is $24.83. Denali Therapeutics has a one year low of $14.56 and a one year high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter last year, the firm earned ($0.72) EPS.

Institutional Trading of Denali Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. CWM LLC raised its position in shares of Denali Therapeutics by 43.6% in the third quarter. CWM LLC now owns 2,153 shares of the company’s stock valued at $63,000 after buying an additional 654 shares during the last quarter. Quest Partners LLC acquired a new position in Denali Therapeutics during the third quarter worth about $73,000. Assetmark Inc. grew its stake in Denali Therapeutics by 18.0% during the 3rd quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock valued at $111,000 after acquiring an additional 580 shares in the last quarter. KBC Group NV raised its holdings in Denali Therapeutics by 75.8% in the 4th quarter. KBC Group NV now owns 6,334 shares of the company’s stock valued at $129,000 after acquiring an additional 2,731 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Denali Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock worth $152,000 after purchasing an additional 920 shares in the last quarter. Institutional investors and hedge funds own 92.92% of the company’s stock.

Insider Activity at Denali Therapeutics

In other news, insider Alexander O. Schuth sold 15,558 shares of the stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $29.91, for a total value of $465,339.78. Following the sale, the insider now owns 178,066 shares in the company, valued at $5,325,954.06. This represents a 8.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Ryan J. Watts sold 29,266 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $20.22, for a total transaction of $591,758.52. Following the completion of the sale, the chief executive officer now directly owns 260,721 shares in the company, valued at approximately $5,271,778.62. The trade was a 10.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 64,518 shares of company stock valued at $1,469,382 in the last three months. 7.90% of the stock is owned by insiders.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.